Pitobrutinib price information and purchasing channel analysis

Pirtobrutinib is a targeted drug used to treat certain types of B cell malignancies, particularly chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). At present, Pitobrutinib has not yet been launched in China, so domestic patients cannot purchase the drug directly through domestic pharmacies for the time being. Despite this, patients can still purchase the drug through some formal overseas channels, but the price difference varies significantly depending on the original drug and the generic drug.

In the US market, the price of the original drug of pitobrutinib is relatively expensive. Taking the specifications of 50mg*30 tablets as an example, the price of the original research version is about 100,000 RMB. Because drug prices are generally higher in the United States, especially imported drugs, the cost of pitobrutinib for patients in the United States may be affected by insurance payments, but even then, patients typically pay higher out-of-pocket costs. For patients without medical insurance, this cost is undoubtedly a heavy burden.

Compared with the original drug, the price of the generic version of pitobrutinib produced in Laos is much lower. According to market information, the price of Laos's generic version of 50mg*30 tablets is about 2000 yuan, which is much lower than the price of the original drug. Although the ingredients are basically the same as the original drugs, generic drugs are more affordable due to lower production costs. For some patients who cannot afford the price of original drugs, choosing generic drugs as an alternative undoubtedly provides a more economical option.

Since Pitobrutinib has not yet been approved for marketing in China, domestic patients cannot purchase the drug directly through regular domestic pharmacies or hospitals. Usually, patients need to rely on overseas drug purchasing channels, such as cross-border e-commerce platforms or purchasing through overseas pharmaceutical agents. When choosing a purchasing channel, patients need to pay special attention to the formality of the channel and the source of the drugs to ensure that they are purchasing legal drugs that meet standards. Informal channels may carry the risk of counterfeit drugs, so patients should try to choose certified sales platforms.

Reference materials:https://www.jaypirca.com/